← Back to Screener
Jasper Therapeutics, Inc. Common Stock (JSPR)
Price$0.97
Favorite Metrics
Price vs S&P 500 (26W)-60.24%
Price vs S&P 500 (4W)-19.76%
Market Capitalization$29.40M
All Metrics
Book Value / Share (Quarterly)$0.15
P/TBV (Annual)2.04x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-2.76
Price vs S&P 500 (YTD)-45.27%
EPS (TTM)$-4.60
10-Day Avg Trading Volume0.84M
EPS Excl Extra (TTM)$-4.60
EPS (Annual)$-3.95
ROI (Annual)-1826.09%
Cash / Share (Quarterly)$1.02
ROA (Last FY)-211.86%
EBITD / Share (TTM)$-4.04
ROE (5Y Avg)-434.52%
Cash Flow / Share (Annual)$-2.76
P/B Ratio7.08x
P/B Ratio (Quarterly)12.34x
Net Income / Employee (Annual)$-1
Net Interest Coverage (TTM)-7.75x
ROA (TTM)-153.67%
EPS Incl Extra (Annual)$-3.95
Current Ratio (Annual)2.62x
Quick Ratio (Quarterly)2.22x
3-Month Avg Trading Volume0.67M
52-Week Price Return-75.00%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.85
52-Week High$7.19
EPS Excl Extra (Annual)$-3.95
26-Week Price Return-56.25%
Quick Ratio (Annual)2.22x
13-Week Price Return-29.05%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.62x
Enterprise Value$0.705
Revenue / Employee (Annual)$0
Cash / Share (Annual)$1.02
3-Month Return Std Dev89.69%
Net Income / Employee (TTM)$-1
ROE (Last FY)-1826.09%
Net Interest Coverage (Annual)-2.07x
EPS Basic Excl Extra (Annual)$-3.95
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-4.60
ROI (TTM)-372.18%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.95
Price vs S&P 500 (52W)-104.83%
Year-to-Date Return-42.62%
5-Day Price Return27.49%
EPS Normalized (Annual)$-3.95
ROA (5Y Avg)-95.93%
Month-to-Date Return19.86%
Cash Flow / Share (TTM)$-0.70
EBITD / Share (Annual)$-3.99
ROI (5Y Avg)-434.52%
EPS Basic Excl Extra (TTM)$-4.60
P/TBV (Quarterly)0.78x
P/B Ratio (Annual)12.34x
Book Value / Share (Annual)$0.15
Price vs S&P 500 (13W)-29.74%
Beta3.30x
Revenue / Share (TTM)$0.00
ROE (TTM)-372.18%
52-Week Low$0.62
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
4.00
4.00
3.93
Industry Peers — Biological Products(89)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
JSPRJasper Therapeutics, Inc. Common Stock | — | — | — | — | $0.97 |
AMGNAmgen Inc | 5.13x | 9.95% | 73.30% | 2.93% | $349.39 |
GILDGilead Sciences Inc | 5.84x | 2.40% | 78.83% | 133.64% | $138.55 |
ARGXargenx SE American Depositary Shares | 12.46x | 89.56% | 150.91% | — | $828.35 |
BNTXBioNTech SE American Depositary Share | 8.75x | -11.81% | 84.21% | — | $102.12 |
BIIBBiogen Inc. Common Stock | 2.60x | 2.22% | 75.69% | -18.77% | $176.02 |
MRNAModerna, Inc. Common Stock | 11.02x | -39.93% | 70.32% | — | $54.68 |
NBIXNeurocrine Biosciences Inc | 4.49x | 21.45% | 98.18% | 2.31% | $128.41 |
EXELExelixis Inc | 4.96x | 6.85% | 96.39% | 31.10% | $44.38 |
TECHBio-Techne Corp. | 7.60x | 1.64% | 66.60% | -20.58% | $57.36 |
HALOHalozyme Therapeutics, Inc. | 5.74x | 37.55% | 83.62% | 22.89% | $66.64 |
About
Jasper Therapeutics is a clinical-stage biotechnology company developing treatments based on hematopoietic stem cell transplantation. The company is developing safer conditioning agents and advanced stem cell engineering technologies to expand the therapeutic applications of stem cell transplantation and ex vivo gene therapy. By improving the safety and efficacy of these procedures, Jasper aims to enable broader patient access to stem cell-based treatments across multiple disease indications.